

# Andrew V Gomez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5462926/publications.pdf>

Version: 2024-02-01

6  
papers

254  
citations

1684188

5  
h-index

1872680

6  
g-index

6  
all docs

6  
docs citations

6  
times ranked

436  
citing authors

#	ARTICLE	IF	CITATIONS
1	FGF21 is required for the metabolic benefits of IKK $\mu$ /TBK1 inhibition. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	7
2	Catecholamines suppress fatty acid re-esterification and increase oxidation in white adipocytes via STAT3. <i>Nature Metabolism</i> , 2020, 2, 620-634.	11.9	25
3	ERR $\beta$ Preserves Brown Fat Innate Thermogenic Activity. <i>Cell Reports</i> , 2018, 22, 2849-2859.	6.4	30
4	Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKK $\mu$ for the treatment of obesity. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5443-5461.	3.0	29
5	Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK $\mu$ and Reveal Mechanisms for Selective Inhibition. <i>Molecular Pharmacology</i> , 2018, 94, 1210-1219.	2.3	36
6	Inhibition of IKK $\gamma$ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. <i>Cell Metabolism</i> , 2017, 26, 157-170.e7.	16.2	127